肺癌1b期目前nccn指南是化疗后靶向治疗奥希替尼,还是单存奥希替尼?

2021-08-05 MedSci原创 MedSci原创

1b期目前nccn指南是化疗后靶向治疗奥希替尼,还是单存奥希替尼-第八个问题.

《梅斯直播课:肺癌诊疗训练营——2021肺癌靶向治疗进展》

回答问题8:1b期目前nccn指南是化疗后靶向治疗奥希替尼,还是单存奥希替尼?

 

欢迎点赞、评论、分享

1b期目前nccn指南是化疗后靶向治疗奥希替尼,还是单存奥希替尼?

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1675273, encodeId=507616e5273df, content=<a href='/topic/show?id=5406125e9c5' target=_blank style='color:#2F92EE;'>#NCCN指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12579, encryptionId=5406125e9c5, topicName=NCCN指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=770f27213437, createdName=yang0219, createdTime=Sun Nov 07 18:36:50 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007428, encodeId=3fbf100e428ff, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210812/426d352aa552429094c8ae32223c1293/f856db0e2d714390aa672d31ab2f151d.jpg, createdBy=9a6b2492830, createdName=12480ee2m89暂无昵称, createdTime=Thu Aug 12 22:00:57 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320187, encodeId=5ba0132018e96, content=<a href='/topic/show?id=c806125e30b' target=_blank style='color:#2F92EE;'>#NCCN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12573, encryptionId=c806125e30b, topicName=NCCN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sat Aug 07 01:36:50 CST 2021, time=2021-08-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1675273, encodeId=507616e5273df, content=<a href='/topic/show?id=5406125e9c5' target=_blank style='color:#2F92EE;'>#NCCN指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12579, encryptionId=5406125e9c5, topicName=NCCN指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=770f27213437, createdName=yang0219, createdTime=Sun Nov 07 18:36:50 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007428, encodeId=3fbf100e428ff, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210812/426d352aa552429094c8ae32223c1293/f856db0e2d714390aa672d31ab2f151d.jpg, createdBy=9a6b2492830, createdName=12480ee2m89暂无昵称, createdTime=Thu Aug 12 22:00:57 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320187, encodeId=5ba0132018e96, content=<a href='/topic/show?id=c806125e30b' target=_blank style='color:#2F92EE;'>#NCCN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12573, encryptionId=c806125e30b, topicName=NCCN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sat Aug 07 01:36:50 CST 2021, time=2021-08-07, status=1, ipAttribution=)]
    2021-08-12 12480ee2m89暂无昵称

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1675273, encodeId=507616e5273df, content=<a href='/topic/show?id=5406125e9c5' target=_blank style='color:#2F92EE;'>#NCCN指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12579, encryptionId=5406125e9c5, topicName=NCCN指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=770f27213437, createdName=yang0219, createdTime=Sun Nov 07 18:36:50 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007428, encodeId=3fbf100e428ff, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210812/426d352aa552429094c8ae32223c1293/f856db0e2d714390aa672d31ab2f151d.jpg, createdBy=9a6b2492830, createdName=12480ee2m89暂无昵称, createdTime=Thu Aug 12 22:00:57 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320187, encodeId=5ba0132018e96, content=<a href='/topic/show?id=c806125e30b' target=_blank style='color:#2F92EE;'>#NCCN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12573, encryptionId=c806125e30b, topicName=NCCN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sat Aug 07 01:36:50 CST 2021, time=2021-08-07, status=1, ipAttribution=)]

相关资讯

RET突变有没有很好疗效的药物?

RET突变有没有很好疗效的药物?-第一个问题

今晚直播:60分钟解读肺癌免疫治疗新近进展

👉 30篇肺癌最新指南报名即得,前200位可申领肿瘤专业纸质书1本

简单介绍小细胞肺癌在靶向治疗的进展

能否简单介绍一下小细胞肺癌在靶向治疗的进展-第五个问题

奥希替尼使用期间,患者临床出现皮疹、腹泻怎么办?可以减量吗?

刚接触奥西替尼的使用,请问治疗期间临床出现皮疹,腹泻明显,可以减量两天一次80mg,还是40mg一天一次-问题2

软脑膜转移恶化的患者怎么选择下一步治疗?

请问软脑膜转移的患者应如恶化选择下一步治疗?还能做靶向吗?-第三个问题.

Ⅳ期肺鳞癌病人治疗方案

Ⅳ期肺鳞癌病人治疗方案-第六个问题

拓展阅读

对于≤2cm的无功能胰腺神经内分泌肿瘤,切还是不切?JAMA子刊最新研究解答!

本研究结果支持手术切除与1.1至2.0cm的NF-PanNET患者生存期的延长有关,这些患者年龄小于65岁、没有共病,并且肿瘤位于远端胰腺。

重磅通知!NCCN 2023 年会日程发布!

会议时间:2023.03.31-04.02 会议地点:佛罗里达州奥兰多

NCCN丨造血生长因子临床实践指南2023.1版(中文)

NCCN 造血生长因子临床实践指南2023.1版(中文)

NCCN丨非小细胞肺癌临床实践指南2023.2版①(中文)

NCCN丨非小细胞肺癌临床实践指南2023.2版①(中文)

2023年第一版乳腺癌NCCN指南出炉!乳腺癌国际前沿治疗局势一览

近日,美国国家综合癌症网络(NCCN)指南更新了2023年第 1 版乳腺癌临床实践指南,此次指南针对乳腺癌的手术治疗、放疗以及药物治疗都进行了修改。